RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat brain lymphoma
Disease control Recruiting nowThis early-phase study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people whose central nervous system lymphoma has come back or not responded to treatment. About 26 adults with this rare cancer will receive the drug combination. The main goal is to …
Matched conditions: RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill combo shows promise for tough brain cancer
Disease control Recruiting nowThis study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with ibrutinib, in adults with relapsed or refractory primary central nervous system lymphoma (PCNSL). The trial has multiple parts to find the safest dose and see if the drug shrinks tumors. …
Matched conditions: RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC